We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-11.74%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$434M
AUM Growth
-$119M
Cap. Flow
-$36.8M
Cap. Flow %
-8.48%
Top 10 Hldgs %
36.01%
Holding
127
New
20
Increased
19
Reduced
51
Closed
12

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$6.21M
2
NVMI
Nova
NVMI
+$5.21M
3
MAZE
Maze Therapeutics
MAZE
+$4.28M
4
IMVT icon
Immunovant
IMVT
+$4.07M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$3.99M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$18.2M
2
MSFT icon
Microsoft
MSFT
+$7.23M
3
META icon
Meta Platforms (Facebook)
META
+$7.12M
4
WIX icon
WIX.com
WIX
+$6.33M
5
MRVL icon
Marvell Technology
MRVL
+$6.16M

Sector Composition

Rank Sector Weight
1 Healthcare 73.67%
2 Technology 12.64%
3 Consumer Discretionary 2.04%
4 Communication Services 2%
5 Utilities 1.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMAT icon
51
Applied Materials
AMAT
$403B
$2.61M 0.6%
+18,000
New +$3.03M
SRRK icon
52
Scholar Rock
SRRK
$5.67B
$2.51M 0.58%
78,193
-12,000
-13% -$462K
CRM icon
53
Salesforce
CRM
$151B
$2.44M 0.56%
+9,100
New +$2.83M
BHVN icon
54
Biohaven
BHVN
$2.03B
$2.4M 0.55%
99,784
-56,710
-36% -$2M
ENGN icon
55
enGene Therapeutics
ENGN
$120M
$2.37M 0.55%
528,365
-31,635
-6% -$196K
SKYE icon
56
Skye Bioscience
SKYE
$20M
$2.35M 0.54%
1,476,353
-88,275
-6% -$241K
WDAY icon
57
Workday
WDAY
$39.6B
$2.34M 0.54%
10,000
– –
SWTX
58
DELISTED
SpringWorks Therapeutics
SWTX
$2.3M 0.53%
52,009
-47,991
-48% -$2.21M
PFE icon
59
Pfizer
PFE
$143B
$2.28M 0.53%
90,000
– –
KURA icon
60
Kura Oncology
KURA
$800M
$2.27M 0.52%
343,522
-266,565
-44% -$2.08M
ELVN icon
61
Enliven Therapeutics
ELVN
$3.92B
$2.2M 0.51%
+111,743
New +$2.4M
TSEM icon
62
Tower Semiconductor
TSEM
$24.8B
$2.19M 0.51%
61,549
-104,600
-63% -$4.73M
UBER icon
63
Uber
UBER
$143B
$2.19M 0.5%
30,000
– –
GOOG icon
64
Alphabet (Google) Class C
GOOG
$4.36T
$2.11M 0.49%
13,500
-30,000
-69% -$5.49M
VKTX icon
65
Viking Therapeutics
VKTX
$3.7B
$2.01M 0.46%
83,270
-20,000
-19% -$632K
COGT icon
66
Cogent Biosciences
COGT
$6.65B
$2.01M 0.46%
+335,024
New +$2.63M
VTGN icon
67
VistaGen Therapeutics
VTGN
$9.89M
$1.98M 0.46%
790,550
-18,000
-2% -$50.9K
AVGO icon
68
Broadcom
AVGO
$1.85T
$1.96M 0.45%
11,695
-5,185
-31% -$1.1M
IONS icon
69
Ionis Pharmaceuticals
IONS
$8.6B
$1.93M 0.44%
63,821
– –
NKE icon
70
Nike
NKE
$61.9B
$1.91M 0.44%
+30,050
New +$2.21M
CHKP icon
71
Check Point Software Technologies
CHKP
$13B
$1.9M 0.44%
8,334
-27,301
-77% -$5.78M
RCKT icon
72
Rocket Pharmaceuticals
RCKT
$340M
$1.81M 0.42%
271,792
– –
RARE icon
73
CALL
Ultragenyx Pharmaceutical
RARE
$2.45B
$1.81M 0.42%
+50,000
New +$2.08M
MSFT icon
74
Microsoft
MSFT
$3.45T
$1.72M 0.4%
4,592
-17,735
-79% -$7.23M
NTR icon
75
Nutrien
NTR
$33.2B
$1.53M 0.35%
30,894
-25,000
-45% -$1.28M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2025 Portfolio in Review

As of Q1 2025, Sphera Funds Management held 127 positions worth $434M, down 21% from $553M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Sphera Funds Management withdrew a net $36.8M in Q1 2025, closing 12 positions and reducing 51 holdings. Its most notable exit was Acadia Pharmaceuticals, an estimated $5.29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 73% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in Maze Therapeutics worth $3.91M.

  • Sphera Funds Management's largest Q1 2025 buy was Maze Therapeutics: 355,554 shares worth $3.91M.
  • Sphera Funds Management added most to Sarepta Therapeutics in Q1 2025, an estimated $6.21M increase.
  • Sphera Funds Management's biggest Q1 2025 reduction was BridgeBio Pharma, cutting an estimated $18.2M.
  • Sphera Funds Management fully exited Acadia Pharmaceuticals in Q1 2025, selling an estimated $5.29M.
  • Sphera Funds Management's ten largest holdings make up 36% of its $434M portfolio in Q1 2025.
  • Sphera Funds Management opened 20 new positions and closed 12 in Q1 2025.
  • Sphera Funds Management's portfolio value fell 21% quarter-over-quarter to $434M.

Based on Sphera Funds Management's 13F filing for Q1 2025, filed 15 May 2025.